Recent Updates — LGVN
On September 16, 2026, Longeveron Inc. announced that its Phase 2b ELPIS II clinical trial for laromestrocel in infants with hypoplastic left heart syndrome (HLHS) failed to meet the primary efficacy endpoint of change from baseline in right ventricular ejection fraction at Month 12. The intent-to-treat analysis showed a least-squares mean difference of -0.7 percentage points between treatment groups, which was not statistically significant (p=0.8336). While exploratory endpoints indicated no deaths in the treated arm versus one in the control group over 12 months and approximately 31% fewer major adverse cardiovascular events, these findings were also not statistically significant. The company plans to analyze additional data and discuss potential next steps with the FDA. Concurrently, Longeveron initiated a process to explore all strategic options to maximize shareholder value, including engaging an investment bank as a strategic advisor and implementing cash conservation measures. Longeveron Inc. is a clinical-stage biotechnology company developing cellular therapies for rare pediatric and aging-related conditions.
Longeveron Inc. announced the effective date for its previously approved one-for-ten reverse stock split of Class A and Class B common stock. The split becomes effective at 11:59 p.m. Eastern Time on August 26, 2026, with split-adjusted trading beginning on August 27, 2026, under the ticker symbol LGVN on the Nasdaq Capital Market. This structural adjustment aims to increase the per-share trading price to regain compliance with Nasdaq’s $1.00 minimum bid price requirement and aligns with institutional investor preferences. The transaction reduces outstanding Class A shares from approximately 30.4 million to 3.0 million and Class B shares from approximately 1.4 million to 144,901. Longeveron is a clinical-stage biotechnology company developing cellular therapies for rare pediatric and chronic aging-related conditions.
Longeveron Inc. appointed Nirav S. Jhaveri as Chief Financial Officer, principal financial officer, and principal accounting officer, effective August 17, 2026. Mr. Jhaveri succeeds Marie Washburn, who returns to her prior role as Vice President and Corporate Controller. His compensation includes a $400,000 annual base salary, a 45% performance-based cash incentive target, and an initial equity award of 300,000 Restricted Stock Units vesting quarterly over three years. Longeveron is a clinical-stage biotechnology company developing cellular therapies for rare pediatric and chronic aging-related conditions.
Longeveron Inc. reported financial and operating results for the three and six months ended June 30, 2026. The company incurred a net loss of $6.1 million for the quarter, compared to $5.0 million in the prior year period. Revenues remained flat at $0.3 million, driven by clinical trial revenue as contract manufacturing revenue ceased. Cash and cash equivalents stood at $10.1 million as of June 30, 2026, with management anticipating this runway will extend into the fourth quarter of 2026. The company is approaching top-line results from its Phase 2b ELPIS II clinical trial for laromestrocel in hypoplastic left heart syndrome, expected in September 2026. Additionally, Longeveron was selected as a finalist and received a $1.0 million Milestone 2 Award from the XPRIZE Healthspan competition. The company operates in the biotechnology industry, developing cellular therapies for rare pediatric and chronic aging-related conditions.